Xiaohui Zeng

1.8k total citations
83 papers, 1.4k citations indexed

About

Xiaohui Zeng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Xiaohui Zeng has authored 83 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in Xiaohui Zeng's work include Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Economic and Financial Impacts of Cancer (13 papers). Xiaohui Zeng is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Economic and Financial Impacts of Cancer (13 papers). Xiaohui Zeng collaborates with scholars based in China, Australia and United Kingdom. Xiaohui Zeng's co-authors include Chongqing Tan, Xiaomin Wan, Liubao Peng, Xia Luo, Qiao Liu, Yucong Zhang, Lidan Yi, Zhen Zhou, Jianhe Li and Siying Wang and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Cancer.

In The Last Decade

Xiaohui Zeng

80 papers receiving 1.3k citations

Peers

Xiaohui Zeng
Mehmet Sitki Copur United States
J. Atkins United States
Sylvie Zanetta France
Lulu Ren Sterling United States
Sandeep Padala United States
R. Sridhara United States
Neeraj Gupta United States
Gideon Steinbach United States
James B. Gerstner United States
Mehmet Sitki Copur United States
Xiaohui Zeng
Citations per year, relative to Xiaohui Zeng Xiaohui Zeng (= 1×) peers Mehmet Sitki Copur

Countries citing papers authored by Xiaohui Zeng

Since Specialization
Citations

This map shows the geographic impact of Xiaohui Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaohui Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaohui Zeng more than expected).

Fields of papers citing papers by Xiaohui Zeng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaohui Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaohui Zeng. The network helps show where Xiaohui Zeng may publish in the future.

Co-authorship network of co-authors of Xiaohui Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaohui Zeng. A scholar is included among the top collaborators of Xiaohui Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaohui Zeng. Xiaohui Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yi, Lidan, Zhen Zhou, Xiaohui Zeng, Chongqing Tan, & Qiao Liu. (2024). First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis. Frontiers in Immunology. 15. 1408928–1408928. 5 indexed citations
2.
3.
Wang, Liting, Peng Ye, Xiaomin Wan, et al.. (2023). First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. PLoS ONE. 18(4). e0279786–e0279786. 6 indexed citations
4.
5.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2022). Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers in Pharmacology. 13. 778505–778505. 19 indexed citations
6.
Liu, Qiao, Xia Luo, Zhen Zhou, et al.. (2021). PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China. Frontiers in Oncology. 11. 745493–745493. 3 indexed citations
7.
Li, Sini, Jianhe Li, Liubao Peng, et al.. (2021). First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis. Clinical Therapeutics. 43(7). 1253–1264.e5. 3 indexed citations
8.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers in Oncology. 11. 743765–743765. 4 indexed citations
9.
Tan, Chongqing, Xia Luo, Sini Li, et al.. (2021). Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. Clinical Rheumatology. 41(1). 63–73. 4 indexed citations
10.
Chen, Zhao, Dongmei Sun, Xiaohui Zeng, et al.. (2020). Selection and evaluation of quality control markers in propolis based on its hyperlipidemia therapy via regulating PXR/CYP3A4 expression. Phytomedicine Plus. 1(1). 100006–100006. 6 indexed citations
11.
Li, Sini, Liubao Peng, Chongqing Tan, et al.. (2020). Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS ONE. 15(5). e0232240–e0232240. 22 indexed citations
12.
Liu, Qiao, Xia Luo, Liubao Peng, et al.. (2020). Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 10(11). e040691–e040691. 8 indexed citations
13.
Zeng, Xiaohui, Xiaomin Wan, Liubao Peng, et al.. (2019). Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open. 9(12). e031019–e031019. 17 indexed citations
14.
Zeng, Xiaohui, et al.. (2019). House dust mite subcutaneous immunotherapy in Chinese patients with allergic asthma and rhinitis. Journal of Thoracic Disease. 11(8). 3616–3625. 10 indexed citations
15.
Chen, Jun, Gaoyun Hu, Zhuo Chen, et al.. (2019). Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Clinical Drug Investigation. 39(10). 931–938. 28 indexed citations
16.
Cai, Tiantian, Ziming Zhao, Xiaodong Chen, et al.. (2018). The gastric mucosal protective effects of astragaloside IV in mnng-induced GPL rats. Biomedicine & Pharmacotherapy. 104. 291–299. 48 indexed citations
17.
Zeng, Xiaohui, Jianhe Li, Liubao Peng, et al.. (2014). Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis. PLoS ONE. 9(2). e88881–e88881. 23 indexed citations
18.
Tan, Chongqing, Liubao Peng, Xiaohui Zeng, et al.. (2013). Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China. PLoS ONE. 8(12). e83396–e83396. 11 indexed citations
19.
20.
Yao, Nan, et al.. (2012). Hypotriglyceridemic effects of apple polyphenols extract via up-regulation of lipoprotein lipase in triton WR-1339-induced mice. Chinese Journal of Integrative Medicine. 20(1). 31–35. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mehmet Sitki Copur Breakdown of academic impact, for papers by J. Atkins Breakdown of academic impact, for papers by Sylvie Zanetta Breakdown of academic impact, for papers by Lulu Ren Sterling Breakdown of academic impact, for papers by Sandeep Padala Breakdown of academic impact, for papers by R. Sridhara Breakdown of academic impact, for papers by Neeraj Gupta Breakdown of academic impact, for papers by Gideon Steinbach Breakdown of academic impact, for papers by James B. Gerstner
Rankless by CCL
2026